Interpace Diagnostics Group Announces Timing of Earnings Release and Investor Conference Call

Wednesday, March 29, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

PARSIPPANY, N.J., March 28, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (the "Company"), a fully

integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, announced today that it will release 2016 year end and fourth quarter financial results on Wednesday, March 29, 2017
after the stock market closes. The Company will also host an investor conference call on Wednesday at 4:30 pm EDT.

Investors, analysts and members of the professional financial community are invited to participate in the call by dialing one of the below numbers:

            Domestic: 1-877-397-0272            International: 1-719-325-4751

            Conference ID: 6214396

A replay of the call will be available for two weeks from 7:30 p.m. ET on March 29, 2017, until 11:59 p.m. ET on April 12, 2017. The number for the replay is (844) 512-2921, or (412) 317-6671 for international calls; the passcode for the replay is 6214396. The audio recording of the call will also be available on the Company's website within 24 hours of the call.

About Interpace Diagnostics Group, Inc.

Interpace is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests: PancraGEN®, for the evaluation of pancreatic cysts and assessment of risk of concomitant or subsequent cancer; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace's mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. For more information, please visit Interpace Diagnostics' website at www.interpacediagnostics.com

CONTACTS:

Interpace DiagnosticsInvestor Relations:

Paul Kuntz[email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/interpace-diagnostics-group-announces-timing-of-earnings-release-and-investor-conference-call-300430683.html

SOURCE Interpace Diagnostics Group, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook